相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
Yan-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Absolute bioavailability of vildagliptin in healthy subjects.
YL He et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
S Ristic et al.
DIABETES OBESITY & METABOLISM (2005)
Patterns of antihypertensive therapy among patients with diabetes
ML Johnson et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes
A Nakashima et al.
XENOBIOTICA (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin - a comparison with tamoxifen
R Darvari et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2004)
Diabetes, hypertension, and cardiovascular disease - An update
JR Sowers et al.
HYPERTENSION (2001)
Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: Comparison with the effects on CYP3A4
M Katoh et al.
PHARMACEUTICAL RESEARCH (2000)
分享论文
